Onkolytische Virotherapie mit Vesikulären Stomatitisviren

Onkolytische Virotherapie - Vesikuläres Stomatitisvirus - Hepatozelluläres Karzinom

oncolytic virotherapy - vesicular stomatitis virus - hepatocellular carcinoma

Literatur

• 1 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny E J, Schmid R M, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.  Hepatology. 2008;  48 1864-1873
• 2 Ebert O, Shinozaki K, Huang T G, Savontaus M J, Garcia-Sastre A, Woo S LC. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.  Cancer Research. 2003;  63 3605-3611
• 3 Ebert O, Shinozaki K, Kournioti C, Park M S, Garcia-Sastre A, Woo S LC. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.  Cancer Research. 2004;  64 3265-3270
• 4 Kirn , et al . Replication-selective virotherapy: biological principles, risk management and future directions.   Nature Medicine. 2001;  7 781-787
• 5 Marozin S, Altomonte J, Stadler F, Thasler W E, Schmid R M, Ebert O. Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3.  Molecular Therapy. 2008;  16 1789-1797
• 6 Shinozaki K, Ebert O, Woo S LC. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.  Hepatology. 2005;  41 196-203
• 7 Stojdl. et al . VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.  Cancer Cell. 2003;  4 263-275